JNJ
stock47Johnson & Johnson
Health Care
Snapshot
Diversified pharmaceuticals and medical-devices company. A defensive dividend aristocrat with broad, durable healthcare franchises.
Long-Term Total Return
iDecade-scale view, dividends reinvested, vs. the S&P 500.
Growth of $10,000 invested at the start of the period, total return (price + reinvested dividends). Illustrative.
Fundamental Trends
Ten-plus years of the figures that drive long-term value.
10-year fundamental trend charts
Track revenue, earnings, free cash flow, ROIC, share count, and dividends over a decade-plus — a Premium research tool.
$9/mo or $84/yr · cancel anytime
Valuation Context
iValuation context
See P/E, P/FCF, and EV/EBITDA against historical and sector medians with Premium.
$9/mo or $84/yr · cancel anytime
Moat Analysis
iPatent-protected drugs, trusted consumer brands, and entrenched hospital relationships in devices provide durable, diversified advantages.
Pharma pipeline and medtech innovation sustain modest but reliable growth.
Risk Factors
What could impair the long-term thesis.
- Patent cliffs on key drugs
- Litigation overhangs
- Pricing/regulatory pressure
Hypothetical Growth
What a past investment would be worth today.
Hypothetical growth calculator
See what an investment made years ago would be worth today, vs. the S&P 500 — a Premium tool.
$9/mo or $84/yr · cancel anytime
Forward Scenario Modeler
Project a starting investment across multi-decade horizons.
Forward scenario modeler
Model conservative, base, and optimistic returns across 10–40 year horizons with Premium.
$9/mo or $84/yr · cancel anytime
Data as of 2025-12-31. Illustrative sample data for research & education — not live market data, and not a recommendation to buy or sell JNJ.